Bioengineered bacteria could lead to therapeutic antibody drugs

A Cornell-led collaboration has devised a potentially low-cost method for producing antibodies for therapeutic treatments. They’ve bioengineered bacteria with an overlooked enzyme that can attach complex sugars, known as glycans, to monoclonal antibodies (mAbs) to boost their immune defenses.

This post was originally published on this site